Abstract: Staphylococcus aureus and Streptococcus pyogenes are gram-positive bacteria that possess great pathogenic potential in humans, causing numerous maladies such as arthritis, cutaneous infections, endocarditis, enterocolitis, food poisoning, pharyngitis, pneumonia, rheumatic fever, surgical site infections, and toxic shock. These prevalent pathogens produce various virulence factors that include the staphylococcal enterotoxins (SEs), toxic shock syndrome toxin-1 (TSST-1), and streptococcal pyrogenic exotoxins (SPEs). Minute (picomolar) amounts of these structurally-similar "superantigens" (SAgs) elicit high levels of proinflammatory cytokines and chemokines that can induce fever, hypotension, and lethal shock. In vitro and in vivo models have provided important tools for studying the biological effects of, and potential vaccines plus therapeutics against, these related protein toxins. This review will delve into the known physical and biological properties of the SEs, TSST-1, and SPEs. The reader will hopefully derive a general appreciation of these wonderfully-complex, structurally-similar toxins produced by S. aureus and S. pyogenes.
INTRODUCTION
Staphylococcus aureus and Streptococcus pyogenes are non-motile, facultative, -hemolytic bacteria that readily colonize skin and various mucosal surfaces via numerous virulence factors [1] [2] [3] [4] . Discerning physical features in broth cultures include grape-like clusters formed by staphylococci versus chains for the streptococci. On agar plates, S. aureus colonies are usually yellow or orange (due to membraneassociated carotenoids), whereas S. pyogenes colonies appear gray and generally smaller. Typical biochemical differences between these bacteria involve catalase production, benzidine reaction, acid production in sugar-containing (lactose, mannitol, ribose, or salicin) broths, and growth in 6.5% NaCl.
From a virulence perspective, and in addition to the staphylococcal enterotoxins (SEs) and toxic shock syndrome toxin-1 (TSST-1) described in detail throughout this review, S. aureus also produces several other virulence factors, for example: capsule, catalase, coagulase, C3-like ADPribosyltransferase (extensively reviewed in another article found in this Bacterial Toxin supplement), hemolysin, hyaluronidase, leukocidin, protein A, and superoxide dismutase [5] . Generation of biofilms by S. aureus, induced by anaerobic conditions plus low iron concentrations, adds yet another degree of difficulty in human attempts at thwarting this bacterium and related species [6] . Due to access issues, S. aureus within biofilms of tissue or implanted medical devices prove particularly resistant to antibiotics and the host's immune system, versus planktonic after ingesting processed meats or dairy products (i.e. ice cream, cottage cheese, custard, cream-filled pastries, etc.) contaminated by S. aureus via improper handling. Upon storage at temperatures that enable bacterial growth, there can be one or more SEs produced as a metabolic byproduct. Released toxin(s), and not the bacterium itself, ultimately causes classic symptoms of staphylococcal food poisoning. Very low microgram quantities of consumed SE are sufficient to cause emesis plus diarrhea within approximately four hours, and one may still experience a general malaise twenty-four to seventy-two hours after ingestion [23, 25] . Food poisoning by SEs is rarely fatal among healthy individuals; however, children and the elderly do represent the highest-risk groups for severe sequelae. Additionally, many MRSA strains (hospital-or community-acquired) also produce various SEs [26] .
In contrast to SEs and food poisoning, toxic shock syndrome (TSS) caused by S. aureus colonization with subsequent TSST-1 release was first reported in 1978 and subsequently linked to tampon usage [27] [28] [29] . Increased levels of protein, carbon dioxide, and oxygen, as well as neutral pH within the microenvironment of S. aureus bound to vaginal epithelium are implicated in TSST-1 production in vivo [22, 30, 31] . An early report erroneously describes TSST-1 as an enterotoxin designated as SEF [32] ; however, homogeneous SEF (later renamed TSST-1) lacks enterotoxicity in non-human primates [33] . Symptoms of staphylococcal TSS are linked to altered immunity that includes: 1) elevated serum levels of proinflammatory cytokines and chemokines; 2) rash (diffuse with intense erythroderma and subsequent desquamation); 3) hypotension (< 90 mm Hg); 4) fever (> 38.9 o C); and 5) adverse effects upon three or more organ systems [1, 2, 28, 30] . Nonmenstrual TSS is also attributed to other SEs, like SEB and SED, from S. aureus growth on other body sites [34, 35] . In fact, non-menstrual TSS is now more prevalent and leads to higher mortality rates versus menstrual cases [35] . Similar to TSST-1, absorption of SEB through the vaginal (as well as nasal and conjunctival) mucosa results in toxic shock symptoms in a mouse model [36] .
From 1980-2005, the percent of women (United StatesMinnesota) vaginally colonized by S. aureus has increased (twelve versus twenty-three percent, respectively) and the toxin profiles of these strains have become different [37] . Antibodies towards two of these toxins (SEG and SEI) are much more evident in women versus men, perhaps suggesting a possible role during vaginal colonization by S. aureus [38] . All TSS patients may suffer recurring bouts unless the offending strain is kept at both minimal growth and toxin release. Antibodies seemingly play an important role in patient susceptibility to TSST-1-induced TSS [39, 40] . Patients that do not seroconvert against the offending toxin are more likely to have relapses of menstrual TSS. Depending upon toxin concentrations, there are varying effects upon human B cells in vitro that include apoptosis and decreased (when used at 1000 pg TSST-1/ml) or enhanced (between 1 -0.01 pg TSST-1/ml) levels of antibody synthesis [41] . Such findings further emphasize a need for vaccines towards not only TSST-1, but also other SEs that play a role in staphylococcal-induced illness [42] [43] [44] [45] [46] [47] [48] [49] [50] .
A microbial relative of S. aureus, S. pyogenes, is a group A streptococcus as defined by classic carbohydrate-based serotyping developed by Rebecca Lancefield [51] . Normal niches for S. pyogenes, like S. aureus, include skin and mucosal surfaces such as the upper respiratory tract. In contrast to S. aureus, S. pyogenes is strictly a human pathogen [52] . S. pyogenes causes various diseases such as acute glomerulonephritis, cellulitis, impetigo, necrotizing fasciitis, pharyngitis, rheumatic fever, and scarlet fever [1, 53, 54] . S. pyogenes possesses potent virulence factors that include: 1) protein toxins (streptolysins O and S); 2) antiphagocytic capsule and cell-wall based M protein; 3) fibronectin binding proteins; as well as 4) a serine-type protease that inactivates the C5a component of complement [54] . The M1 serotype is often linked to outbreaks and much of the gene diversity between S. pyogenes strains is attributed to prophage DNA, which includes macrolide (erythromycin) resistance [55] . As later described, S. pyogenes produces multiple streptococcal pyrogenic exotoxins or SPEs (A, C, G-M) that are also prophageencoded and possess similar biological (superantigenic) effects as the aforementioned S. aureus SEs and TSST-1 [1, 2] . In particular, the SPEs are linked to streptococcal TSS during bouts of bacteremia, necrotizing fasciitis (most common route of S. pyogenes-induced TSS), or rheumatic fever [1, 56] . Like that for S. aureus TSST-1 and menstrual TSS, antibodies against SPEs and M protein also play an important role in protective immunity against invasive group A streptococcal infections [57] . Circulating toxin can cause a characteristic rash (i.e. scarlet fever) as a consequence of host-induced inflammatory mediators and dilated blood vessels. For example, scarlet fever is most prevalent in children following wound or upper respiratory infections by S. pyogenes, with SPEA-producing strains often the culprit followed by SPEC producers [58, 59] .
The term "superantigen" (SAg) commonly describes the SEs, TSST-1, SPEs or any other microbial protein that activates specific T-cells at sub-picogram per ml levels in vitro [1, 2, 60, 61] . Typical SAg interactions with host cells differ from conventional antigens, in that the former: 1) directly bind outside the peptide-binding groove of major histocompatibility complex (MHC) class II; 2) exert biological effects without internalization and cellular processing; as well as 3) are not MHC class II restricted. For the latter, there are differences between types of class II molecules and effective presentation of toxin to T cells [1, 2, 60] . Recognition of a SAg -MHC class II complex by T cells through T-cell receptor (TCR) depends upon the variable region within a TCR chain (V ), thus differing from the V -V chain combination common for conventional peptide antigens [1, 2, 62] . Microbial SAgs are reportedly produced by various gram-positive plus gramnegative bacteria [63] [64] [65] [66] [67] [68] [69] , viruses [70] [71] [72] [73] [74] , and even fungi [75] . However, of all the SAgs found in the literature, those from staphylococci and streptococci are generally better studied and best fit the classic definition of a SAg. For this particular review, our use of SAg will be interchangeable with SE, TSST-1, and SPE. The widespread nature of these microbial proteins with similar biological effects is highly suggestive of a successful survival strategy shared throughout the biosphere.
GENETICS AND STRUCTURES OF SAgs
The SEs, TSST-1 and SPEs are secreted, single-chain proteins (twenty-three to thirty kilodaltons each) that cluster into distinct, amino acid-based homology groups [1, 2, 60] . Genes for these staphylococcal and streptococcal toxins are encoded by plasmids, bacteriophage, or mobile genetic elements and typically expressed during late logarithmic, into stationary, phases of growth [1, 2, 59, 76] . Differential gene location and in situ release of SEs and TSST-1 from S. aureus evidently cause noticeable differences in neutralizing antibody responses toward these toxins [77] . Some of the S. aureus SAgs (SEG, SEI, and SE-like proteins M, N, O, U) not commonly associated with TSS are encoded by an enterotoxin gene cluster (egc) within a pathogenicity island. Often, strains producing egc-based SAgs are harmless commensals. Additionally, the egc-associated toxins are released during logarithmic growth in vitro (versus late stationary phase for non-egc toxins like SEA, SEB, SEC, TSST-1) and, relative to non-egc toxins, do not readily stimulate production of neutralizing antibodies amongst human carriers of egc-containing strains of S. aureus [77, 78] . Regulation, in vitro or in vivo, of egc and non-egc SAgs is not well understood.
Structural genes for the SPEs are found on the chromosome or integrated bacteriophages. Promiscuous transfer of SPE genes by phage occurs between different group A strains, as well as to groups C and perhaps G streptococci, thus logically leading to increased virulence among normally avirulent strains [79] . Like that for S. aureus SAgs, the regulation of SPE genes is also not well understood [1] . A global regulator gene (nra or negative regulator of group A streptococci) maximally expressed during early stationary phase affects SPEA, binding proteins for fibronectin and collagen, as well as a positive regulator gene mga (multiple gene regulator of group A) [80] . SAg production varies between strains of S. pyogenes in vitro, while a host factor(s) evidently plays a role in toxin synthesis in situ. For instance, synthesis of SPEC and DNase by S. pyogenes may be naturally enhanced during infection by an unknown, human-derived factor(s) from pharyngeal cells [81] .
X-ray crystallography of the SEs, TSST-1, and SPEs reveals a conserved, globular conformation consisting of two tightly-packed domains containing -sheet plus -helix structures (Fig. 1) . The domains are separated by a conserved, amphipathic -helix of the -grasp fold forming a shallow groove that interacts with surface loops on TCR [82] [83] [84] [85] . The amino terminus contains an OB-fold while the carboxy terminus has -grasp domains. In terms of general evolutionary relationships, the OB-fold family of protein domains consists of a five-stranded, closed -barrel that commonly uses the same face for ligand binding and as an active site [86] . The prominent -sheet and open barrel-like structure of the -grasp fold control domain function [87] . Structure-function studies provide additional clues regarding specific residues critical for binding to MHC class II and TCR [45, 49, [88] [89] [90] . Upon considering overall similarities among bacterial SAgs, protein surfaces that involve interactions with MHC class II tend to be most conserved [91] . Furthermore, these SAgs share antigenic structures as evidenced by cross-reactivity and neutralization with polyclonal and monoclonal antibodies [92] [93] [94] [95] [96] .
BINDING OF SAgs TO CELLS
Staphylococcal and streptococcal SAgs bind distinct MHC class II molecules with relatively high affinity (K d = 10 -8 -10 -6 M) [1, 2] . The HLA-DR (human class II) molecule binds better to SEs and TSST-1, versus HLA-DP or -DQ, while the preferential binding of SPEA to HLA-transfected L-cells is HLA-DQ > -DR > -DP. Competitive binding studies reveal at least two different binding sites on MHC class II molecules for the SEs and TSST-1. Among the SEs, SEA has the highest affinity for HLA-DR mediated by two separate binding sites [97] [98] [99] . The higher affinity site on SEA is within the C-terminus and binds HLA-DR chain in a Zn 2+ -dependent manner [98] . The second binding site of SEA for HLA-DR is similar to that for SEB and located within the N-terminus, which interacts with the chain of HLA-DR [99] . Cross-linking of two MHC class II molecules by a SAg leads to cytokine expression in monocytes [100] [101] [102] [103] .
Although analogous N-terminal regions from SEB and TSST-1 bind to MHC class II [89, 90, 104] , co-crystals of SEB or TSST-1 complexed to HLA-DR1 reveal distinct differences [101, 102] . Uniquely, SEB interacts exclusively with the chain of HLA-DR1 and is unaffected by presentation of peptide antigen. TSST-1 binds to both and chains of class II molecules and is affected by residing peptide antigen. SPEA also differs from most other SPEs by binding to the , not , chain of MHC class II. A Zn +2 molecule generally serves an important role in SPE binding and subsequent biological effects, with SPEC being an exception [1, 105] . Although SPEC uses Zn +2 -dependent binding to MHC II, this is not essential for T-cell activation and suggests Zn +2 -independent interactions [105] . The evolutionary similarity between streptococcal and staphylococcal SAgs is further evidenced in SPEH, as this "hybrid" toxin consists of an N-terminal domain related to the SEB homology group and a C-terminus resembling SPEC [88] .
The groove formed between SE, TSST-1, or SPE domains represents an important binding site for TCR V chain [83-85, 89, 90, 101] . These toxins typically bind (approximately 10 -6 M affinity) to a distinct repertoire of Vbearing T-cells, thus generating a "fingerprint" useful for diagnosing staphylococcal-and streptococcal-induced TSS [106] [107] [108] . The SAg -MHC class II complex binds to the carbon backbone, but not side-chain residues, of TCR V [62, 109, 110] . There is one notable exception, as SEH binds to T cells via V interactions [111] . An additional unique characteristic of SEH is the sub-nanomolar affinity for MHC class II [112] . Depending upon the SAg, there are differences in how antigen presenting cells (APCs) and T cells interact [113] . For instance, SPEC or TSST-1 form a bridge between cells while the MHC class II and TCR molecules do not make direct contact. In contrast, SEB does not inhibit direct MHC class II -TCR interactions.
HOST CELL RESPONSES TO SAgs
Recognition of the SAg -MHC class II complex by T cells results in signaling, profound proliferation, and ultimately cytokine production by APCs plus T cells [1, 2] . Peripheral blood mononuclear cells (PBMCs) from humans are commonly used in vitro to study cell activation by staphylococcal and streptococcal SAgs [114] [115] [116] [117] [118] [119] . PBMCs secrete various cytokines / chemokines following SAg exposure, and these include interleukin (IL)-1, -2, -6, tumor necrosis factor (TNF) , TNF , interferon (IFN) , macrophage inflammatory protein 1 (MIP-1 ), MIP-1 , and monocyte chemoattractant protein-1 (MCP-1). T-cell recognition of SAg, when bound to an APC through MHC class II, becomes the triggering event for cytokine and chemokine release [114, [120] [121] [122] . Contradictions exist in the literature though, regarding APC and T-cell responses to these toxins without the other cell type [114, 123] . MHC class II-based stimulation of T cells by SAgs is a general requirement, but cells possessing select TCR V types (i.e. human 6, 7, and 18 with SEA) can also independently respond, albeit less efficiently [124] . Perhaps the MHC class II-dependent V types require class II molecules for more effective cell activation to overcome lower binding affinity to TCR? Additionally, SAg (i.e. SEB) presentation to V 3 + T-cells without MHC class II-bearing cells can also decrease TCR expression and induce anergy [125] .
In addition to APCs and T cells, bacterial SAgs can also have both stimulatory and destimulatory effects upon B cells and synovial fibroblasts. For example, cross-linking of TCR with MHC class II triggers B-cell proliferation and immunoglobulin synthesis in a dose-dependent manner, but high concentrations of toxin actually inhibit antibody synthesis [41, 126] . Continual SE exposure during chronic rhinosinusitis linked to S. aureus colonization can lead to localized, toxin-specific IgE and shifting of IgG subclasses (i.e. elevated IgG4 and decreased IgG2 versus individuals without SE-specific IgE) [127] . Early exposure to SEs as a neonate, via colonization by toxinogenic S. aureus, may also play an important role in oral tolerance and food allergies [128] . Suppression of antibody secretion by TSST-1 occurs by inducing apoptosis among B cells [41] , critically impacting humoral immunity against this toxin that can lead to recurring bouts of TSS [39, 40] . Direct stimulation of synovial fibroblasts by SAgs also induces chemokine expression, suggesting that autoreactivity and chemotactic responses could initiate or augment chronic inflammation such as rheumatoid arthritis [129] [130] [131] . Additionally, intestinal myofibroblasts respond directly to SEA (but not SEB) by producing MCP-1, IL-6, and IL-8 which is also an effect mimicked by cross-linking MHC class II molecules with antibody [132] . Overall, bacterial SAgs can have multiple effects upon various aspects of the host's immune system.
IN VIVO EFFECTS OF SAgs
From a food poisoning perspective with SEs, specific cells and receptors in the intestinal tract have not been identified unequivocally. Data suggest that leukotrienes play a role in SEB-induced emesis and skin reactions (non-human primate model) while serotonin binding to vagal afferent neurons plus the cannabinoid receptor 1 affect SEA-induced emesis (shrew model) [133, 134] . The SEs readily induce emesis in primates (human and non-human) upon ingesting low microgram quantities, while larger toxin amounts can lead to toxic shock [23, 135] . Studies with SEs and nonhuman primates are considered the gold standard for in vivo work linked to food poisoning; however, these efforts are increasingly more expensive (politically and monetarily) and thus fuel exploration by various laboratories for alternative animal models (Table 1) . Typically, TSST-1 or SPEs do not cause vomiting after ingestion although they do naturally cause TSS in humans and animals [1, 2, 33, 136] . An oral dose of SEB activates V 8 + T-cells in Peyer's patches of mice, increasing IFN and IL-2 mRNA expression [137] . Either SEA or SEB alone causes intestinal inflammation, but these toxins can also exacerbate a microbe-based syndrome called inflammatory bowel disease which suggests an immune response to ingested SEs [138] . An enteric immune connection may also explain fifty year-old results published by Sugiyama et al. [139] , as they discovered that non-human primates given intragastric SE become transiently resistant to another dose of the same (but not a different) SE. Such findings are likely linked to toxin-specific stimulation of unique V -bearing T-cells that subsequently become anergic.
To further understand how SE ingestion affects intestinal mucosa, in vitro studies with human Caco-2 monolayers reveal transcytosis (albeit by different mechanisms) of SEA, SEB, and TSST-1 [140] . In this model system, there is facilitated transport of SEB and TSST-1 in a bidirectional fashion (i.e. basolateral to apical or vice versa). Transport of SEA is in contrast less rapid and non-specific. Mutant forms of SEB altered at residues Asn23Lys or Phe44Ser, which respectively decrease toxin binding to TCR and MHC class II, also decrease transcytosis by fifty to seventy percent. In this same report, additional studies with mice show that ingested SEB enters the circulatory system (peak levels appear approximately two hours after ingestion) at much higher concentrations (twenty-fold) than SEA. The SEs do not act as direct cytotoxins upon human intestinal cells [141] , but they do disturb gut mucosa by increasing ion permeability in the presence of SE-stimulated PBMCs and cytokine / chemokine release in vitro [142] .
Perhaps in contrast to the above transcytosis results, SE binding to MHC class II may not play a role in enterotoxicity. Attenuated variants of SEA (Leu48Gly) and SEB (Phe44Ser), with diminished binding to MHC class II molecules and decreased stimulation of T cells, remain emetic [143] . Although carboxymethyl modification of histidines on SEA [144] and SEB [145] minimally affect superantigenicity, these molecules lack enterotoxicity, lethal effects, and skin reactivity [133, 146, 147] . In non-human primates, this modified SEB inhibits vomiting and diarrhea of wild-type SEB when given together, perhaps suggesting competition for a common receptor(s) in the gut [146] . Individual recombinant changes of His44, His50, His114, or His187 on SEA to either alanine or aspartic acid have no effect upon biological activity, yet modification of His225 impacts both emesis and superantigenicity [147] .
Besides toxin-specific resistance after an oral dose of SE, chronic intravenous exposure functionally inactivates all Vreactive T-cells in mice [148] . Footpad injections of SEB in mice also elicit a dose-related tolerance within sixteen hours among circulating V 8 + T-cells [149] . Subcutaneous exposure to low doses of SEB in mice causes a general immunosuppression inhibited by IL-12 [150] . IL-12, produced by dendritic cells and macrophages, plays many roles that include differentiation of T cells. Additionally, immunosuppression induced by repeated exposure to SEB is also linked to activation of regulatory T-cells (Foxp 3+ plus CD152 high ) and catabolism of tryptophan by indoleamine-2,3-dioxygenase [151] .
Similar to SEB, mice given a microgram of SEA intranasally (once a week for three weeks) also become resistant to a subsequent lethal challenge of SEA, but not TSST-1 [152] . Such tolerance is not due to toxin-specific antibody or functional deletion of SEA-reactive T-cells. However, increased IL-10 levels in sera from these animals correlate with other findings showing that this cytokine protects against SE or TSST-1 intoxication [153, 154] . T-cell studies of patients with rheumatic fever (acute/chronic), or healthy donors, show varying degrees of stimulation (or lack of) by SPEA in vitro [155] . Overall, dampening of host immunity is a general characteristic of the staphylococcal and streptococcal SAgs which possibly enhances pathogen survival.
SAgs perturb the immune system by inducing high levels of proinflammatory cytokines in various animals that include primates, rabbits, and mice (Table 1) [1, 2, 23, 46, 47, [116] [117] [118] [156] [157] [158] [159] . IL-1 and TNF are endogenous pyrogens that induce fever via hypothalamus release of prostaglandin E2 [160] . Circulating levels of IFN , IL-2, and IL-6 also increase after toxin exposure. IFN particularly feeds into SAg-fueled toxicity by increasing MHC class II expression among various cell types (i.e. APCs, epithelial cells, and endothelial cells), plus augmenting the proinflammatory actions of IL-1 and TNF . SAg-driven TSS results from a cacophony of released cytokines plus chemokines that adversely affect critical organs throughout the body [1, 2] .
Mice represent an alternative model to large vertebrates (i.e. non-human primates or rabbits) for studying SAgmediated shock (Table 1 ) [156, [161] [162] [163] [164] [165] [166] . Relative to non- [213, 217] human primates, mice are a very viable option for basic toxin studies involving potential vaccines and therapeutics. However, mice lack an emetic response and are thus less appropriate for studying certain aspects of food poisoning due to SEs. Mice are also naturally less susceptible than primates to SAgs, largely because of decreased affinity for murine MHC class II [1, 2] . Various groups have shown that potentiating agents like D-galactosamine, actinomycin D, lipopolysaccharide (LPS), viruses (influenza and lymphocytic choriomeningitis), or even pathogenic protozoa (Trypanosoma cruzi, causative agent of Chagas disease) greatly amplify SAg toxicity and TSS effects in mice [161] [162] [163] [164] [165] [166] [167] [168] . The natural synergy between SAgs with diverse pathogens, including outer membrane-based LPS of gramnegative bacteria, provides yet additional intrigue for truly understanding complex microbe-host interactions.
For many years our laboratory has favored a LPSpotentiated model in mice, as various studies show a natural synergy existing between SAgs and LPS [153, 161, 162, 167, [169] [170] [171] [172] [173] . Very minute (nanogram) quantities of LPS alone in humans elevate cytokine levels, temperature, and heart rate [174] , yet SAgs like the SEs, TSST-1, and SPEs can dangerously augment LPS effects many log-fold [157] . Upon considering the sheer number of gram-negative bacteria that make up intestinal flora, along with a recognized increase of such bacteria among TSS patients, the probability of SAg(s) and LPS synergy is rather high [157, 175] . There is a correlation between elevated serum levels of various proinflammatory cytokines (IL-1, IL-2, TNF , IFN ) with severity of SEA-, SEB-, or TSST-1-induced TSS [2, 42, 61, 156, 162] . Further studies with knockout mice show that IL-10 affects various cytokine and chemokine (MIP-1 and MIP-2) levels in serum following SEB intoxication [176] . Two different receptors for TNF play differential roles in SE-induced shock, as p55 (type 1) serves a more prominent role versus p75 (type 2) [153] . Various cell markers such as CD28 (also known as TP44), CD43 (leukosialin), CD54 (intercellular adhesion molecule-1 or ICAM-1), and CD95 (Fas or cell death receptor) also have prominent functions in SAg-induced shock in vivo [177] [178] [179] [180] [181] [182] .
An additional twist to using mice for studying staphylococcal and streptococcal SAgs involves transgenics expressing human receptors, such as HLA-DQ6 and CD4. These animals succumb to normally sublethal amounts of SEB (with D-galactosamine potentiation), and the serum levels of TNF correlate with onset of lethal shock [183] . Transgenics expressing human HLA-DR3 and CD4 lethally respond to a SE challenge without a potentiating agent, thus providing a more easily-interpreted model [184] . When naïve PBMCs from these transgenics are incubated with SEB in vitro, IL-6 and IFN release is markedly elevated versus that from cells of control (non-transgenic) BALB/c mice. As reported from other animal models for staphylococcal and streptococcal SAgs, these results with HLA-DR3/CD4 mice suggest involvement of proinflammatory cytokines. Similar studies using transgenic mice, with similar results, have also been reported using SPEA and mice expressing human HLA-DQ8 plus CD4 [185] . Additionally, transgenics overexpressing TCR V 3 (murine) experience increased mortality from elevated TNF and IFN levels during infection by SEA-producing S. aureus [186] . Mice expressing human HLA and CD4, or even increased levels of specific murine TCR, will likely provide a clearer understanding of SAg-mediated effects in vivo without potentiating agents.
Besides lethality, temperature represents an important parameter for studying SE-or TSST-1-induced shock in various animal models ( Table 1 ). In mice, these studies can be accomplished by implanting a subcutaneous transponder [153] or intraperitoneal telemetry device [187] . Results reveal a rapid (less than 10 hours after toxin challenge) temperature decrease that provides a quick, non-lethal parameter for intoxication. Mouse studies have not unveiled a temperature increase following intoxication by a SE, in contrast to non-human primates given SEB [188] , thus suggesting a very rapid onset of SE-induced TSS in mice and subtle differences between models.
In addition to overt signs of SAg intoxication in vivo (i.e. temperature, emesis, diarrhea, and death), SEB induces apoptosis and decreased signal transduction among specific V -bearing T-cells due to loss of L-selectin (a cell adhesion molecule) [189, 190] . Surface levels of TCR-CD3 also decrease approximately fifty percent among V -reactive Tcells within just thirty minutes after SEB exposure [191] . Tcell proliferation in mice following an SEB injection is transient, as within forty-eight hours the majority of activated T-cells undergo apoptosis [61] . After two intraperitoneal injections (one hundred micrograms each) of SEB into mice, splenic V 8 + T-cells become non-responsive to SEB in vitro. These cells produce less IL-2, but more IFN and IL-10, within forty-eight hours after the initial toxin dose [192] . In contrast to elevated levels of proinflammatory IFN , anti-inflammatory IL-10 perhaps reflects an attempt by the host to counter deleterious effects of other cytokines and chemokines.
In addition to numerous studies with mice ( Table 1) , rabbits have also afforded a reliable in vivo model for SAginduced TSS although little information exists regarding SAg interactions with rabbit MHC class II and TCR [165, 172, [193] [194] [195] [196] [197] [198] . For rabbits, use of an implanted infusion pump to slowly release toxin into the body mimics a natural setting during S. aureus or S. pyogenes infection [193, 195] . Variation in strain susceptibility to a specific toxin exists in rabbits (New Zealand White versus Dutch-Belted), just like that discovered in mice [153, 196] . Similar to humans, rabbits exposed to either TSST-1 or SEB develop elevated serum levels of LPS eliminated by polymyxin B, along with diminished clinical signs of TSS [169, 196, 197] . Higher concentrations of circulating LPS may be due to impaired liver clearance [172, 198] , further exacerbated by SAgs like the SEs, TSST-1, or SPEs [170, 199] .
Other less-defined animal models for SAg intoxication have been described in the literature ( Table 1) . One example includes goats used for TSST-1 and SEB, with fever as a measurable parameter after intravenous administration [200] . There is also a reported ferret model for oral intoxication that employs relatively large (milligram) quantities of SEB, using emesis and fever as markers [201] . Another emetic model for the SEs employs the rather unusual house musk shrew challenged intraperitoneally or orally [202] . Recently, this latter model has been used successfully for vaccine studies with recombinantly-attenuated SEA [203] . An obvious, and less than pleasant, caveat with any emetic (or diarrheic) model involves quantitation.
Although basic aspects of intoxication have been investigated in each animal model listed above (Table 1) , critical work still remains for vaccine and therapeutic discovery. Any model (in vitro or in vivo!) has positive, but also negative, aspects that require any investigator to closely scrutinize data and interpret usefulness of such information for human application.
THERAPEUTICS AND VACCINES AGAINST SAgs
Other than a precarious societal reliance upon antibiotics, which continue to become less practical with rising microbial resistance, there are surprisingly few clinicallyuseful options for therapeutics and there are no approved vaccines targeting the staphylococcal and streptococcal SAgs. To circumvent SAg stimulation, potential therapies and vaccines against these toxins should interfere with one or more of the following: 1) TCR -SAg -MHC class II interactions; 2) accessory, co-stimulatory, or adhesion molecules necessary for T-cell activation; and 3) proinflammatory cytokine plus chemokine release from host cells.
Several of the aforementioned models (in vitro and in vivo) have been used to study potential therapies against SAg-induced TSS. As just a few examples that uniquely attack SAg-induced TSS, inhibitors of nitric oxide synthase (i.e. aminoguanidine or dexamethasone) can diminish SEAinduced IL-1, -2, -6, TNF, and IFN production from human PBMCs in vitro, as well as prevent neutrophil influx into rat lungs in vivo [204, 205] . The blocking of CD28 costimulatory receptor by a synthetic ligand, CTLA4-Ig, prevents TSST-1-induced effects in vitro and in vivo [206] . Antibodies against TNF prevent SEB-induced lethality [156] , while IL-10 blocks IL-1, TNF , as well as IFN synthesis that then reduces TSS symptoms [154] . Studies with human PBMCs in vitro and a mouse model show that either pentoxifylline or pirfenidone (drugs that diminish proinflammatory cytokine synthesis) effectively decreases SEB or TSST-1 toxicity [116, 117] . Tryptanthrin, naturally derived from a medicinal plant, is an anti-inflammatory alkaloid that inhibits cyclooxygenase 2 (COX2) and decreases IFN release from SEB-stimulated lymphocytes in Peyer's patches [207] . A hexapeptide (anti-leukinate) inhibitor of IL-8, a cytokine which elicits SEA-induced inflammation of the lungs, decreases neutrophil influx and subsequent lung damage [208] . Finally, soluble antagonists for TCR V have also proven effective in vitro and in vivo (rabbit model) against SEB [209] . These reagents were generated from a murine V 8.2 clone that was affinity matured into small (twelve kilodalton), higher-affinity (six log lower K d versus wild-type) molecules through random mutagenesis.
Besides the aforementioned experimental therapeutics, different antibody-based therapies and experimental vaccines that directly target SAgs have been developed over many decades. Preexisting antibodies toward these toxins play an important role in disease outcome [39, 40, 210] , and intravenous immunoglobulin (IVIG) has been useful following the onset of TSS due to S. aureus or S. pyogenes infection [211, 212] . From a bioterror perspective involving an aerosol of SEB, passive transfer of SEB-specific antibodies to naïve rhesus monkeys within four hours after exposure prevents TSS [213] . Similar results were discovered earlier in mice, suggesting important parallels between diverse animal models for aerosol or intraperitoneal administration of SEB [214] . Recombinantly-attenuated forms of staphylococcal and streptococcal SAgs that ineffectively bind MHC class II and/or specific V TCR represent promising vaccines against TSS [42-50, 203, 215-217] . When given either parenterally [44, 45, 50, 203] , or mucosally [43, 218] , such vaccines are effective against a toxin challenge or S. aureus infection; however, mucosal vaccination with these toxin-based immunogens has remained largely unexplored. In addition to recombinant vaccines for SAgs, dated literature reveals that formaldehyde toxoids of SEA, SEB, or SEC1 also represent effective parenteral or mucosal immunogens [219, 220] . Although chemically-generated toxoids of the SEs and many other toxin antigens exist, such treatment can adversely affect native epitopes, antigen processing, and subsequent presentation to the immune system [221, 222] . In our opinion, intimate knowledge of how a toxin interfaces with receptor (i.e. co-crystal or structure/function data) leads to minimal manipulations of the toxin into an immunogen that best retains proper conformation and epitopes.
CONCLUSIONS
S. aureus and S. pyogenes are very formidable pathogens that cause a wide array of diseases, including TSS [113] . One common, protein-based aspect these bacteria share involves synthesis of toxic SAgs. Intoxication by SEs, TSST-1, or SPEs occurs through the host's abnormal response to the offending toxin (i.e. elevated proinflammatory cytokine / chemokine levels), that can trigger shock and possibly death. After cytokine and chemokine release, ensuing imbalance of the immune system likely aids survival of the offending pathogen [223] . Similar sequence homologies, conformations, and biological activities amongst the staphylococcal and streptococcal SAgs suggest common evolution as well as a common means of medicinally thwarting their intoxication process. New SAgs from S. aureus and S. pyogenes are constantly being discovered by groups from around the world. More effective controls targeting S. aureus, S. pyogenes, plus their associated toxins are necessary and include new therapeutics as well as vaccines. Many of the latter forms of medicine remain experimental, with promise for the not so distant future. In particular, human monoclonal antibodies that target SAgs and are well characterized could be quite efficacious as well as afford distinct advantages versus IVIG.
Finally, the constant evolution of pathogens like S. aureus and S. pyogenes requires that humans co-evolve towards recognizing and then effectively challenging these constantly changing, and quite deadly, microbial threats. The SEs, TSST-1, and SPEs portrayed in this review represent just one piece of a complex puzzle towards better management of staphylococcal and streptococcal infections.
